Literature DB >> 26719290

Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Brian E Powers1, Ramon Velazquez1, Christy M Kelley2, Jessica A Ash1, Myla S Strawderman1, Melissa J Alldred3,4, Stephen D Ginsberg3,4,5, Elliott J Mufson6, Barbara J Strupp7.   

Abstract

Individuals with Down syndrome (DS) exhibit intellectual disability and develop Alzheimer's disease-like neuropathology during the third decade of life. The Ts65Dn mouse model of DS exhibits key features of both disorders, including impairments in learning, attention and memory, as well as atrophy of basal forebrain cholinergic neurons (BFCNs). The present study evaluated attentional function in relation to BFCN morphology in young (3 months) and middle-aged (12 months) Ts65Dn mice and disomic (2N) controls. Ts65Dn mice exhibited attentional dysfunction at both ages, with greater impairment in older trisomics. Density of BFCNs was significantly lower for Ts65Dn mice independent of age, which may contribute to attentional dysfunction since BFCN density was positively associated with performance on an attention task. BFCN volume decreased with age in 2N but not Ts65Dn mice. Paradoxically, BFCN volume was greater in older trisomic mice, suggestive of a compensatory response. In sum, attentional dysfunction occurred in both young and middle-aged Ts65Dn mice, which may in part reflect reduced density and/or phenotypic alterations in BFCNs.

Entities:  

Keywords:  Aging; Attention; Basal forebrain cholinergic neurons; Choline acetyltransferase; Down syndrome; Trisomic mice

Mesh:

Substances:

Year:  2015        PMID: 26719290      PMCID: PMC4929047          DOI: 10.1007/s00429-015-1164-y

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  78 in total

1.  The efficiency of systematic sampling in stereology--reconsidered.

Authors:  H J Gundersen; E B Jensen; K Kiêu
Journal:  J Microsc       Date:  1999-03       Impact factor: 1.758

2.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

3.  Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

Authors:  Ahmad Salehi; Jean-Dominique Delcroix; Pavel V Belichenko; Ke Zhan; Chengbiao Wu; Janice S Valletta; Ryoko Takimoto-Kimura; Alexander M Kleschevnikov; Kumar Sambamurti; Peter P Chung; Weiming Xia; Angela Villar; William A Campbell; Laura Shapiro Kulnane; Ralph A Nixon; Bruce T Lamb; Charles J Epstein; Gorazd B Stokin; Lawrence S B Goldstein; William C Mobley
Journal:  Neuron       Date:  2006-07-06       Impact factor: 17.173

4.  Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.

Authors:  Patrizia Bianchi; Elisabetta Ciani; Sandra Guidi; Stefania Trazzi; Daniela Felice; Gabriele Grossi; Mercedes Fernandez; Alessandro Giuliani; Laura Calzà; Renata Bartesaghi
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

5.  Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function.

Authors:  L A Hyde; D F Frisone; L S Crnic
Journal:  Behav Brain Res       Date:  2001-01-08       Impact factor: 3.332

Review 6.  Down syndrome: advances in molecular biology and the neurosciences.

Authors:  G T Capone
Journal:  J Dev Behav Pediatr       Date:  2001-02       Impact factor: 2.225

7.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

8.  Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands.

Authors:  J McGaughy; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

9.  The topography of plaques and tangles in Down's syndrome patients of different ages.

Authors:  D M Mann; P O Yates; B Marcyniuk; C R Ravindra
Journal:  Neuropathol Appl Neurobiol       Date:  1986 Sep-Oct       Impact factor: 8.090

Review 10.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

View more
  11 in total

1.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

2.  Maternal choline supplementation in a mouse model of Down syndrome: Effects on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring.

Authors:  Brian E Powers; Christy M Kelley; Ramon Velazquez; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neuroscience       Date:  2016-11-10       Impact factor: 3.590

3.  Cystatin C prevents neuronal loss and behavioral deficits via the endosomal pathway in a mouse model of down syndrome.

Authors:  Gurjinder Kaur; Sebastien A Gauthier; Rocio Perez-Gonzalez; Monika Pawlik; Amol Bikram Singh; Benjamin Cosby; Panaiyur S Mohan; John F Smiley; Efrat Levy
Journal:  Neurobiol Dis       Date:  2018-09-01       Impact factor: 5.996

4.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

Review 5.  Neuroprotective Effects of Choline and Other Methyl Donors.

Authors:  Rola A Bekdash
Journal:  Nutrients       Date:  2019-12-06       Impact factor: 5.717

Review 6.  Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease.

Authors:  Jose L Martinez; Matthew D Zammit; Nicole R West; Bradley T Christian; Anita Bhattacharyya
Journal:  Front Aging Neurosci       Date:  2021-07-12       Impact factor: 5.702

7.  Forebrain Shh overexpression improves cognitive function and locomotor hyperactivity in an aneuploid mouse model of Down syndrome and its euploid littermates.

Authors:  Feng J Gao; Donna Klinedinst; Fabian-Xosé Fernandez; Bei Cheng; Alena Savonenko; Benjamin Devenney; Yicong Li; Dan Wu; Martin G Pomper; Roger H Reeves
Journal:  Acta Neuropathol Commun       Date:  2021-08-16       Impact factor: 7.801

8.  Temporal and brain region-specific elevations of soluble Amyloid-β40-42 in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Savannah Tallino; Wendy Winslow; Samantha K Bartholomew; Ramon Velazquez
Journal:  Aging Cell       Date:  2022-03-15       Impact factor: 9.304

9.  Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer's Disease.

Authors:  Melissa J Alldred; Sai C Penikalapati; Sang Han Lee; Adriana Heguy; Panos Roussos; Stephen D Ginsberg
Journal:  Mol Neurobiol       Date:  2021-07-14       Impact factor: 5.682

10.  Maternal Choline Supplementation as a Potential Therapy for Down Syndrome: Assessment of Effects Throughout the Lifespan.

Authors:  Brian E Powers; Ramon Velazquez; Myla S Strawderman; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Front Aging Neurosci       Date:  2021-10-06       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.